Study of CAR T-cell therapy for refractory ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new treatment called universal allogeneic CAR T-cell therapy (QT-019C) for adults with severe, hard-to-treat immune thrombocytopenia (ITP). It aims to see if targeting CD19 and BCMA on immune cells can safely improve platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had ITP for at least 6 months, and your platelet count has been very low (less than 30) on two separate tests in the last 15 days.
- You have a specific antibody against your own platelets (anti-platelet glycoprotein autoantibody).
- You have tried standard treatments (like steroids, IVIG, TPO-RA, rituximab, or spleen removal) and they didn't work well enough or stopped working.
- Your heart, kidney, and liver function are mostly normal, and your blood counts and oxygen levels are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This trial tests a combination of two drugs—a CD20 monoclonal antibody (targets certain immune cells) and a BTK inhibitor (blocks a protein involved in immune cell signaling)—to treat immune-related cytopenias (low blood cell counts caused by your immune system). The drugs aim to reduce abnormal immune activity and help your body make more healthy blood cells.
This trial tests a new mRNA-based treatment for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The treatment aims to lower the immune attack and raise platelet counts.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This trial tests a new type of immune cell therapy (CAR-T cells) for people with chronic or refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if this treatment can safely raise platelet counts and reduce bleeding risk.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.